United States · Investor

Cormorant Capital

Last cheque observed Jul 2026; 26 cheques on record.

Email

Deploying nowNew fund $5.5M, Mar 2011VC firm

SeedSeries ASeries BGeneticsPharmaceuticalReal Estate

Deploying now
100%of best year1cheques in 12 months, 26 on record
Since the last cheque116days00hrs00min00sec
Median round$69MRounds led0 of 26Mostly inUnited States, 85%
Pitch Cormorant Capital

Cormorant Capital highlights

  1. 01

    1 cheques in the last 12 months

  2. 02

    Mostly Series C and Series B: 85% of its rounds

What they do

Type
VC firm (from a list, unverified)
Cheque size
Not stated
Stages
SeedSeries ASeries BGrowth
Sectors
GeneticsPharmaceuticalReal Estate
Based in
New York, United States
Cold pitches
Not stated

The record

Every round we can evidence, newest first26 appearances

  1. 2026

    1 round

  2. Jul
    FORE BiotherapeuticsSeries D · US · Ventureburn$67MWith 15 others
  3. 2019

    3 rounds

  4. Jul
    Revolution MedicinesSeries C · US · FinSMEs$100MWith 9 others
  5. Apr
    Sasuma PharmaceuticalsUS · Biospace$62MWith 9 others
  6. Jan
    BridgeBioUS · FinSMEs$299MWith 6 others
  7. 2018

    13 rounds

  8. Dec
    Akero TherapeuticsSeries B · US · FinSMEs$70MWith 9 others
  9. Nov
    HarpoonSeries C · US · FinSMEs$70MWith 7 others
  10. Oct
    Stoke TherapeuticsSeries B · US · FinSMEs$90MWith 7 others
  11. Oct
    TP TherapeuticsUS · FinSMEs$80MWith 6 others
  12. Sept
    AtrecaSeries C · US · FinSMEs$125MWith 7 others
  13. Aug
    RenoviaUS · FinSMEs$42MWith 4 others
  14. Aug
    Orchard TherapeuticsSeries C · GB · FinSMEs$150MWith 14 others
  15. Jun
    CibusSeries C · US · FinSMEs$70MWith 2 others
  16. Jun
    PrecisionSeries B · US · FinSMEs$110MWith 18 others
  17. Apr
    CorvidiaSeries B · US · FinSMEs$60MWith 8 others
  18. Apr
    ConstellationUS · FinSMEs$100MWith 12 others
  19. Apr
    EdiosSeries B · US · FinSMEs$64MWith 6 others
  20. Apr
    CMABSeries B · CN · FinSMEs$34MWith 3 others
  21. 2017

    9 rounds

  22. Nov
    TricidaSeries D · US · FinSMEs$58MWith 7 others
  23. Sept
    AutolousSeries C · GB · FinSMEs$80MWith 4 others
  24. Sept
    BridgeBioUS · FinSMEs$135MWith 5 others
  25. Sept
    ReplimuneSeries B · US · FinSMEs$55MWith 6 others
  26. Jul
    AxonicsSeries C · US · FinSMEs$21MWith 2 others
  27. Jun
    Zai LabSeries C · CN · FinSMEs$30MWith 2 others
  28. Mar
    Solid BiosciencesSeries C · US · FinSMEs$50MWith 6 others
  29. Mar
    908 DevicesGrowth · US · FinSMEs$20MWith 6 others
  30. Jan
    Scholar RockSeries C · US · FinSMEs$47MWith 7 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

Named by the firm itself, on a filing, its Form ADV or its company registration2 named

AMAlex MayrusManaging Member of General PartneriFiling they signed
RARichard A MayrusManaging Member of General PartneriFiling they signed

We also hold 2 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

Who they invest alongside

The investors most often in the same rounds as Cormorant Capital. A count of rooms they were both in, not a relationship either has claimed.

FidelityVC firm4rounds togetherOrbiMedPrivate equity4rounds togetherWellington ManagementVC firm4rounds togetherBoxer CapitalVC firm3rounds togetherCasdin CapitalVC firm3rounds togetherPerceptive VenturesVC firm3rounds togetherRedmile GroupVC firm3rounds togetherSR OneCorporate VC3rounds togetherVenrockVC firm3rounds togetherAIGCorporate VC2rounds togetherAlexandria Real Estate EquitiesVC firm2rounds togetherApple Tree PartnersVC firm2rounds together

Recently backed

The latest companies Cormorant Capital put money into.

FORE Biotherapeutics$67M · Jul 2026Revolution Medicines$100M · Jul 2019BridgeBio$299M · Jan 2019Akero Therapeutics$70M · Dec 2018Harpoon$70M · Nov 2018Stoke Therapeutics$90M · Oct 2018

Quick answers about Cormorant Capital

What does Cormorant Capital invest in?

Cormorant Capital invests most often at Series C and Series B (85% of the rounds on record), in sectors such as Genetics, Pharmaceutical and Real Estate.

How active is Cormorant Capital?

26 investments on record, 1 of them in the last 12 months. The most recent was in Jul 2026.

What has Cormorant Capital invested in recently?

Its most recent investments on record: FORE Biotherapeutics (Series D, Jul 2026), Revolution Medicines (Series C, Jul 2019) and Sasuma Pharmaceuticals (Undisclosed round, Apr 2019).

How big are Cormorant Capital's cheques?

The median round it joins is $69M.

Does Cormorant Capital lead rounds?

Rarely, if at all: none of its 26 investments on record names it as the lead.

Where does Cormorant Capital invest?

Most of the companies it backs are in the United States (85%), the United Kingdom (8%) and China (8%).

Is Cormorant Capital investing now?

Yes: it is actively investing, with 1 investments in the last 12 months.

Who does Cormorant Capital invest alongside?

Most often Fidelity (4 rounds together), OrbiMed (4 rounds together) and Wellington Management (4 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it